Safety Extension Study to Evaluate the Biodegradation of the Brimonidine Tartrate Posterior Segment Drug Delivery System.
Phase of Trial: Phase II
Latest Information Update: 07 Jan 2016
At a glance
- Drugs Brimonidine (Primary)
- Indications Glaucoma; Ocular hypertension
- Focus Pharmacodynamics
- Sponsors Allergan
- 29 Apr 2014 Status changed from active, no longer recruiting to completed, as per ClinicalTrials.gov record.
- 05 Feb 2014 Planned End Date changed from 1 Mar 2014 to 1 Apr 2014 according to ClinicalTrials.gov record.
- 15 Mar 2012 Actual patient number is 215 according to ClinicalTrials.gov.